In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. David H. Ilson argues that epirubicin and other anthracyclines no longer have a place in the treatment of GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
Author: admin
A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that the optimal pre-operative therapy for esophagus and GE junction cancers is chemotherapy alone. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses the molecular subtyping/profiling of upper-GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016” Dr. James C. Yao argues that bevacizumab cannot treat pancreatic neuroendocrine tumors (pNET). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Diane Reidy-Lagunes argues that everolimus does not have a role in the treatment of carcinoid tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. James C. Yao argues that everolimus has a role in carcinoid tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Mark Andrew Dickson discusses the management of GIST tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael J. Hall discusses genetics in gastrointestinal cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Luis A. Diaz discusses the use of liquid biopsies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses novel therapies for gastrointestinal malignancies beyond immunotherapy. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that biomarkers beyond MSI cannot direct immunotherapy in gastrointestinal malignancies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt discusses inflammation in colorectal cancer (CRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that TAS-102 followed by regorafenib is the preferred salvage therapy for metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that the preferred salvage therapy for metastatic colorectal cancer (mCRC) is regorafenib followed by TAS-102. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that borderline-resectable liver metastasis in RAS wild-type colorectal cancer (CRC) should be treated with a chemo doublet with EGFR inhibitor. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that borderline-resectable liver metastasis in RAS wild-type colorectal cancer (CRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that radioembolization of colorectal cancer (CRC) liver-limited metastases is not ready for use in the first line. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that radioembolization of colorectal cancer (CRC) liver-limited metastases is ready for use in the first line. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that there is no optimal first-line therapy sequence in metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that there is an optimal sequence for first-line therapy in metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that biomarkers do not have a role in the adjuvant setting for colorectal cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses the use of biomarkers for colon cancer treatment selection. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Charles B. Simone examines novel forms of radation delivery, and whether technology can trump biology in the treatment of disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass arguest that a trimodality approach is preferred for the treatment of locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski proposes that a bimodality approarch is preferential for the treatment of locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski discusses whether or not the choice of systemic agents or their sequencing makes a different in combined modality therapy for locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass discusses the mangement of the mediastinum and other surgical issues. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.
In this presentatino, Dr. Gerard A. Silvestri outlines his perspective on the updated TNM classifications for malignant tumors, and expounds upon whether there is a role for histology of markers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.
In this presentation from the “20th Annual Perspectives in Thoracic Oncology” Dr. Laura Jean Bierut examines current strategies for curtailing smoking addiction. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Benjamin Levy queries whether liquid biopsy will replace conventional tissue-based sampling. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. William K. Evans discusses the current cost and efficacy of managing non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sven de Vos disuccese new agents for use in the treatment of recurrent follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg argues against the use of maintenance rituximab for the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Gilles Salles argues that maintenance rituxumab should be used in the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Thomas E. Witzig discusses how he sequence therapy in the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jia Ruan examines the best approach to the initial therapy of peripheral t-cell lymphoma (PTCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presenation, Dr. Kami Maddocks discusses who should get what for upfront therapy of mantle cell lymphoma (MCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Adam M. Petrich discusses the best approach to treat double hit/double protein expression diffuse large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John P. Leonard discusses the hurdles to using cell of origin in the classification and treatment of diffuse large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Laurie H. Sehn discusses the best approach to limited stage diffuse large b-cell lymphoma (DLBCL), and whether that includes radiation. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Randy Gascoyne discusses the future of lymphoma pathology in the era of tumor profliing. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg discusses the highlights from the 2015 International Conference on Malignant Lymphoma, held in Lugano Switzerland. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete responses (CRs) in patients with chronic lymphocytic leukemia (CLL) following long-term treatment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve M. Ansell discusses the use of immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien argues that there is no value to the use of brentuximab vedotin as consolidation therapy following auto-SCT in Hodgkin Lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies” Dr. Robert W. Chen argues that there is value to using brentuximab vedotin as consolidation therapy shorlty following auto-SCT in Hodgkin Lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jeremy Abramson argues that chemotherapy-based regiments are the preferred second-line approach to induce lymphoma remission prior to stem cell transplant (SCT). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Allison Moskowitz argues that single-agent brentuximab is the best second-line approach to induce lymphoma remission prior to stem cell transplant (SCT). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.